Skip to main content

Table 2 The survival time, depending on the demographic and clinical factors (multivariate analysis)

From: Quality of life during chemotherapy, hormonotherapy or antiHER2 therapy of patients with advanced, metastatic breast cancer in clinical practice

Variable

Risk ratio (95%Cl)

p

ECOG performance status

1,54 (1,21-1,98)

0,01

Type of therapy

0,82 (0,61-1,02)

0,08

Age

0,91 (0,74-1,16)

0,11

Education

1,01 (0,81-1,21)

0,94

Place of residence

1,10 (0,78-1,42)

0,71

Treatment centre

1,05 (0,75-1,45)

0,88

Smoking status

0,91 (0,80-1,02)

0,19

Response to treatment

0,64 (0,44-0,83)

< 0,001